TRAVERT 10% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRAVERT 10% IN PLASTIC CONTAINER (TRAVERT 10% IN PLASTIC CONTAINER).
Travert 10% (invert sugar) provides a source of carbohydrate calories and water for hydration. Invert sugar is hydrolyzed to glucose and fructose, which are metabolized via glycolysis and the Krebs cycle to produce ATP. It also promotes glycogen deposition and spares protein catabolism.
| Metabolism | Invert sugar is rapidly hydrolyzed to glucose and fructose by invertase in the intestine or administered directly IV. Glucose and fructose are metabolized via glycolysis and the Krebs cycle in the liver and peripheral tissues. Fructose is primarily metabolized in the liver via fructokinase to fructose-1-phosphate, then to trioses entering glycolysis or gluconeogenesis. |
| Excretion | Primarily renal as unchanged drug (approx. 90%) and as metabolites (approx. 10%). Fecal excretion is negligible (<1%). |
| Half-life | 0.3-0.7 hours (20-40 minutes) in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | Approximately 0% (not bound to plasma proteins due to high polarity). |
| Volume of Distribution | 0.25-0.3 L/kg; distributes primarily in extracellular fluid volume. |
| Bioavailability | Not applicable; administered only by intravenous route (100% bioavailability by definition). |
| Onset of Action | Intravenous: immediate onset within minutes. |
| Duration of Action | 1-2 hours following a single dose; sustained infusion maintains effect while infusing. |
Intravenous infusion: 500-1000 mL of 10% solution administered over 1-3 hours, repeated as needed based on fluid and electrolyte requirements.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in anuria; in oliguric patients, use with caution and monitor fluid balance; no dose adjustment specified for GFR-based modifications. |
| Liver impairment | No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment due to risk of fluid overload. |
| Pediatric use | Intravenous infusion: 2-5 mL/kg of 10% solution, administered over 1-3 hours, repeated as clinically indicated. |
| Geriatric use | Due to decreased renal function and higher risk of fluid overload, use lower initial doses and monitor electrolytes and fluid status closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRAVERT 10% IN PLASTIC CONTAINER (TRAVERT 10% IN PLASTIC CONTAINER).
| Breastfeeding | Dextrose is a normal component of breast milk and is not expected to cause adverse effects in the breastfed infant when administered intravenously to the mother. The M/P ratio is not clinically relevant as dextrose is endogenously regulated. No special precautions are needed. |
| Teratogenic Risk | Intravenous dextrose solutions are essential for maternal and fetal hydration and caloric support. No teratogenic effects have been reported with standard clinical use. However, rapid correction of maternal hypoglycemia or hyperglycemia may cause fetal hyperinsulinism or rebound hypoglycemia. Use with caution in conditions associated with fluid overload (e.g., preeclampsia). Fetal monitoring is recommended during administration in compromised pregnancies. |
■ FDA Black Box Warning
Solutions containing invert sugar should not be administered simultaneously with blood through the same infusion set because of the possibility of agglutination or hemolysis.
| Serious Effects |
["Hypersensitivity to any component","Severe dehydration with hypernatremia","Anuria or oliguria","Acute delirium tremens (due to fructose metabolism)","Patients with fructose intolerance (hereditary fructose intolerance or fructose-1,6-diphosphatase deficiency)"]
| Precautions | Use with caution in patients with hepatic or renal impairment, metabolic disorders (e.g., diabetes mellitus), or fluid/electrolyte imbalances. Monitor blood glucose and electrolytes. Rapid infusion may cause hyperglycemia, osmotic diuresis, or hyperosmolar syndrome. Do not administer if solution is discolored or contains particulates. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose and electrolyte levels, especially in diabetic or glucose-intolerant patients. Assess fluid balance and signs of fluid overload (edema, pulmonary crackles). Fetal heart rate monitoring is recommended during use in pregnancy complicated by gestational diabetes or fetal compromise. Observe for maternal hyperglycemia or hypoglycemia after infusion. |
| Fertility Effects | No adverse effects on fertility have been reported with intravenous dextrose solutions at therapeutic doses. No data suggest impairment of reproductive function. Dextrose is a physiological energy source and does not interfere with reproductive hormones or gametogenesis. |